Pseudo-continuous arterial spin labelling shows high diagnostic performance in the detection of postoperative residual lesion in hyper-vascularised adult brain tumours.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
May 2020
Historique:
received: 11 12 2018
accepted: 20 09 2019
revised: 26 08 2019
pubmed: 23 1 2020
medline: 3 11 2020
entrez: 23 1 2020
Statut: ppublish

Résumé

Our aim was to evaluate the contribution of pseudo-continuous arterial spin labelling (pCASL) in the detection of a postoperative residual lesion in adult brain tumours. Seventy-five patients were prospectively included. Following the results of preoperative DSC-PWI assessment, intra-axial lesions, including high-grade gliomas (n = 43) and certain metastases (n = 14), were classified as hyper-vascular (HV+ group, n = 57); other lesions, including low-grade gliomas and certain metastases, were classified as non-hyper-vascular (HV- group, n = 18). To confirm the absence/presence of a residual lesion or disease progression, postoperative MRI including pCASL sequence and follow-up-MRI were performed within 72 h and 1-6 months after the resection, respectively. Two raters evaluated the images. Mean and maximal ASL cerebral blood flow (CBF) values were measured in the perioperative region and normalised to the contralateral tissue. The pCASL-CBF maps and post-contrast T1WI were visually assessed for residual lesion. Quantitative data were analysed with unpaired Student t and Mann-Whitney U tests and the visual diagnostic performance with the McNemar test. In the HV+ group, the mean normalised CBF was 1.97 ± 0.59 and 0.97 ± 0.29 (p < 0.0001, AUC = 0.964, cut-off = 1.27) for patients with or without residual tumours, respectively. The mean normalised CBF was not discriminative for assessing residual tumours in the HV- group (p = 0.454). Visual CBF evaluation allowed 92.98% patients belonging to the HV+ group to be correctly classified (sensitivity 93.02%, specificity 92.86%, p < 0.001). Visual evaluation was correlated with contrast enhancement evaluation and with the mean normalised CBF values (r = 0.505, p < 0.0001 and 0.838, p < 0.0001, respectively). Qualitative and quantitative ASL evaluation shows high diagnostic performance in postoperative assessment of hyper-perfused tumours. In this case, postoperative pCASL may be useful, especially if contrast injection cannot be performed or when contrast enhancement is doubtful. • Evaluation of postoperative residual lesion in the case of brain tumours is an imaging challenge. • This prospective monocentric study showed that increased normalised cerebral blood flow assessed by pseudo-continuous arterial spin labelling (pCASL) correlates well with the presence of a residual tumour in the case of hyper-vascular tumour diagnosed on preoperative MRI. • Qualitative and quantitative pCASL is an informative sequence for hyper-vascular residual tumour, especially if acquired more than 48 h after brain tumour surgery, when contrast enhancement can give ambiguous results due to blood-brain barrier disruption.

Identifiants

pubmed: 31965259
doi: 10.1007/s00330-019-06474-4
pii: 10.1007/s00330-019-06474-4
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2809-2820

Références

Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
PLoS One. 2015 Aug 21;10(8):e0136380
pubmed: 26296086
PLoS One. 2018 Jan 17;13(1):e0191341
pubmed: 29342201
Oncotarget. 2018 Apr 6;9(26):18570-18577
pubmed: 29719627
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
Eur Radiol. 2018 Aug;28(8):3306-3317
pubmed: 29536240
AJR Am J Roentgenol. 1998 Dec;171(6):1479-86
pubmed: 9843274
J Neurosurg. 2014 Nov;121(5):1115-23
pubmed: 25192475
BMC Med Imaging. 2017 Feb 1;17(1):10
pubmed: 28143434
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Eur Radiol. 2018 Sep;28(9):3801-3810
pubmed: 29619520
JAMA Oncol. 2016 Nov 1;2(11):1460-1469
pubmed: 27310651
World Neurosurg. 2018 Apr;112:e702-e710
pubmed: 29408648
Neurosurg Focus. 2014 Dec;37(6):E3
pubmed: 25434388
Neuroradiology. 2010 Apr;52(4):307-17
pubmed: 19841916
Clin Radiol. 2017 Mar;72(3):255-261
pubmed: 27932251
AJNR Am J Neuroradiol. 2007 Oct;28(9):1683-9
pubmed: 17893221
Neuroradiology. 2015 Nov;57(11):1135-44
pubmed: 26280515
AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51
pubmed: 25907520
Eur Radiol. 2013 Jun;23(6):1467-77
pubmed: 23314599
Radiology. 2003 Aug;228(2):523-32
pubmed: 12819338
Neuroimage Clin. 2017 Apr 25;15:136-142
pubmed: 28507896
PLoS One. 2016 Nov 18;11(11):e0166662
pubmed: 27861605
Radiology. 2016 Nov;281(2):337-356
pubmed: 27755938
J Neurooncol. 2017 Oct;135(1):161-171
pubmed: 28685405
Neuroradiology. 2015 Dec;57(12):1181-202
pubmed: 26351201
AJNR Am J Neuroradiol. 2017 Oct;38(10):1876-1883
pubmed: 28729293
Neuroradiology. 2006 Mar;48(3):150-9
pubmed: 16470375
Magn Reson Med. 2015 Jan;73(1):102-16
pubmed: 24715426
Acta Radiol. 2013 May;54(4):448-54
pubmed: 23592805
Acta Neurochir (Wien). 2015 Sep;157(9):1573-80
pubmed: 26156037
Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v
pubmed: 21109143
J Neurosurg. 2013 Apr;118(4):801-8
pubmed: 23373806
Eur J Radiol. 2017 Dec;97:31-36
pubmed: 29153364
J Neurooncol. 2014 Jun;118(2):363-367
pubmed: 24736830
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670
pubmed: 27742108
Radiology. 2017 Feb;282(2):610-612
pubmed: 28099109
Cochrane Database Syst Rev. 2018 Jan 22;1:CD011551
pubmed: 29357120
J Neurooncol. 2017 Aug;134(1):213-219
pubmed: 28567589
Exp Ther Med. 2016 Jun;11(6):2432-2436
pubmed: 27284331
J Neuroimaging. 2014 Jan-Feb;24(1):23-30
pubmed: 22672084
Eur Radiol. 2018 Oct;28(10):4334-4342
pubmed: 29654561
J Neurosurg. 2010 Jan;112(1):10-7
pubmed: 19361270
AJNR Am J Neuroradiol. 2011 Dec;32(11):2073-9
pubmed: 21960503
Neurosurgery. 2017 Sep 1;81(3):397-415
pubmed: 28486641
Eur J Radiol. 1999 May;30(2):115-24
pubmed: 10401592
Acta Neurochir (Wien). 2013 Mar;155(3):389-97
pubmed: 23325516
Eur Radiol. 2011 Jul;21(7):1526-34
pubmed: 21331595
MAGMA. 2011 Aug;24(4):211-23
pubmed: 21594585
Eur J Radiol. 2016 Sep;85(9):1545-53
pubmed: 27501887

Auteurs

Clara Cohen (C)

Neuroradiology Department, Centre Hospitalo-Universitaire de Tours, 2 boulevard Tonnellé, 37000, Tours, France. clara.cohen.cc@gmail.com.

Bruno Law-Ye (B)

Neuroradiology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.

Didier Dormont (D)

Neuroradiology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.
Sorbonne Université, UPMC Univ Paris 06, F-75013, Paris, France.

Delphine Leclercq (D)

Neuroradiology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.

Laurent Capelle (L)

Neurosurgery Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.

Marc Sanson (M)

Neurooncology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.

Damien Galanaud (D)

Neuroradiology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.
Sorbonne Université, UPMC Univ Paris 06, F-75013, Paris, France.

Nadya Pyatigorskaya (N)

Neuroradiology Department, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France.
Sorbonne Université, UPMC Univ Paris 06, F-75013, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH